Cargando…
Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients
The preexistence of humoral immunity, which cross-reacts with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein due to prior endemic low-pathogenic human coronavirus infection, has been reported, but its role in coronavirus disease 2019 (COVID-19) outcomes remains elusive. We eval...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267280/ https://www.ncbi.nlm.nih.gov/pubmed/35807155 http://dx.doi.org/10.3390/jcm11133870 |
_version_ | 1784743680560594944 |
---|---|
author | Yamashita, Taro Shimakami, Tetsuro Nio, Kouki Terashima, Takeshi Okajima, Masaki Taniguchi, Takumi Wada, Takashi Honda, Masao Gabata, Toshifumi Ota, Kenji Yanagihara, Katsunori Kaneko, Shuichi |
author_facet | Yamashita, Taro Shimakami, Tetsuro Nio, Kouki Terashima, Takeshi Okajima, Masaki Taniguchi, Takumi Wada, Takashi Honda, Masao Gabata, Toshifumi Ota, Kenji Yanagihara, Katsunori Kaneko, Shuichi |
author_sort | Yamashita, Taro |
collection | PubMed |
description | The preexistence of humoral immunity, which cross-reacts with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein due to prior endemic low-pathogenic human coronavirus infection, has been reported, but its role in coronavirus disease 2019 (COVID-19) outcomes remains elusive. We evaluated serum samples obtained from 368 patients before the pandemic and 1423 independent serum samples from patients during the pandemic. We found that approximately 6~13% and 1.5% of patients had IgG cross-reactivity to the SARS-CoV-2 spike and nucleocapsid proteins in both cohorts. We evaluated the IgG cross-reactivity to the SARS-CoV-2 spike and nucleocapsid proteins in 48 severe or critical COVID-19 patients to evaluate if the elevation of IgG was evoked as a primary response (IgG elevation from 10 days after antigen exposure) or boosted as a secondary response (IgG elevation immediately after antigen exposure). Approximately 50% of patients showed humoral immune responses to the nucleocapsid protein of SARS-CoV-2. Importantly, none of the critically ill patients with this humoral immunity died, whereas 40% of patients without this immunity did. Taken together, subjects had humoral immunity to SARS-CoV-2 nucleocapsid but not spike before the pandemic, which might prevent critically ill COVID-19 patients from dying. |
format | Online Article Text |
id | pubmed-9267280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92672802022-07-09 Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients Yamashita, Taro Shimakami, Tetsuro Nio, Kouki Terashima, Takeshi Okajima, Masaki Taniguchi, Takumi Wada, Takashi Honda, Masao Gabata, Toshifumi Ota, Kenji Yanagihara, Katsunori Kaneko, Shuichi J Clin Med Article The preexistence of humoral immunity, which cross-reacts with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein due to prior endemic low-pathogenic human coronavirus infection, has been reported, but its role in coronavirus disease 2019 (COVID-19) outcomes remains elusive. We evaluated serum samples obtained from 368 patients before the pandemic and 1423 independent serum samples from patients during the pandemic. We found that approximately 6~13% and 1.5% of patients had IgG cross-reactivity to the SARS-CoV-2 spike and nucleocapsid proteins in both cohorts. We evaluated the IgG cross-reactivity to the SARS-CoV-2 spike and nucleocapsid proteins in 48 severe or critical COVID-19 patients to evaluate if the elevation of IgG was evoked as a primary response (IgG elevation from 10 days after antigen exposure) or boosted as a secondary response (IgG elevation immediately after antigen exposure). Approximately 50% of patients showed humoral immune responses to the nucleocapsid protein of SARS-CoV-2. Importantly, none of the critically ill patients with this humoral immunity died, whereas 40% of patients without this immunity did. Taken together, subjects had humoral immunity to SARS-CoV-2 nucleocapsid but not spike before the pandemic, which might prevent critically ill COVID-19 patients from dying. MDPI 2022-07-04 /pmc/articles/PMC9267280/ /pubmed/35807155 http://dx.doi.org/10.3390/jcm11133870 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yamashita, Taro Shimakami, Tetsuro Nio, Kouki Terashima, Takeshi Okajima, Masaki Taniguchi, Takumi Wada, Takashi Honda, Masao Gabata, Toshifumi Ota, Kenji Yanagihara, Katsunori Kaneko, Shuichi Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients |
title | Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients |
title_full | Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients |
title_fullStr | Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients |
title_full_unstemmed | Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients |
title_short | Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients |
title_sort | preexisting humoral immunity cross-reacting with sars-cov-2 might prevent death due to covid-19 in critical patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267280/ https://www.ncbi.nlm.nih.gov/pubmed/35807155 http://dx.doi.org/10.3390/jcm11133870 |
work_keys_str_mv | AT yamashitataro preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT shimakamitetsuro preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT niokouki preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT terashimatakeshi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT okajimamasaki preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT taniguchitakumi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT wadatakashi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT hondamasao preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT gabatatoshifumi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT otakenji preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT yanagiharakatsunori preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients AT kanekoshuichi preexistinghumoralimmunitycrossreactingwithsarscov2mightpreventdeathduetocovid19incriticalpatients |